Prot #M16-049: An Open-label Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis

Project: Research project

Project Details

StatusFinished
Effective start/end date11/19/19 → 8/31/23

Funding

  • AbbVie Inc. (Prot #M16-049)